跳至主要内容
临床试验/CTRI/2024/04/066324
CTRI/2024/04/066324尚未招募2 期

Tumor microenvironment modulation therapy in breast-cancer-subtypes and single-cell genomics-based patient stratification for improved low-dose immunotherapy: Preclinical and Clinical study - NI

Indian Council of Medical Research0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Women aged 18 and above with Breast Cancer of the subtypes Luminal B Her2-ve and TNBC
  • 2.Women with advanced stages of Luminal B Her2-ve and TNBC that are inoperable but non-metastatic
  • 3.Women with Luminal B Her-ve and TNBC that are eligible for NACT

排除标准

  • Exclusion Criteria:
  • 1.Women with early-stage Luminal B Her-ve and TNBC tumors that are taken up for primary surgery will be excluded
  • 2.Women with Luminal B tumors that are HER2 positive will be excluded
  • 3.Women with Luminal A tumors will be excluded
  • 4.Women with the above subtypes of BC having HIV, HCV, and HBV infections will be excluded from the study
  • 5.Women undergoing treatment for BC or any other types of cancer will be excluded
  • 6.Women with any other cancers will be excluded

研究者

相似试验